Adovate

A message from our CEO, William Stilley . . . Adovate is pleased to announce that it has been awarded an $800,000 grant from Virginia Catalyst to advance ADO-5030 into Phase 2 clinical trials for the treatment of Clostridioides difficile (C. diff) infections. This funding supports our collaboration with the University of Virginia and Virginia Tech to develop a meaningful treatment for C. diff infections. ? C. diff affects approximately 500,000 patients annually in the U.S., resulting in nearly 30,000 deaths (CDC 2023). The Centers for Disease Control and Prevention classified CDI as an antimicrobial-resistant pathogen and an “urgent” public health threat due to its increasing prevalence and the rising incidence of recurrent infections. The economic burden of CDI is substantial, with inpatient costs exceeding $1 billion annually. Despite the high burden of disease, the current standard of care remains broad-spectrum antibiotics, which fail to restore a healthy gut microbiome and often lead to recurrent infections. ? With C. diff posing a significant public health challenge, we believe our lead drug candidate, ADO-5030, has the potential to transform treatment options for patients at risk of recurrent infections. ? The full press release can be found at the following link:?https://lnkd.in/exPxmrz7. ? The Virginia Catalyst conducts an extensive and competitive grant award process, and we are grateful and honored that Adovate’s were selected to receive this award from among the numerous other highly qualified applicants. ? This is the second $800,000 Virginia Catalyst award received by Adovate, with the first being to develop ADO-5030 as a treatment for asthma. The Phase 1 human clinical safety trial of ADO-5030 has commenced, and we look forward to beginning testing in in patients in the coming months.

Excited to announce that Adovate will be attending the 43rd Annual J.P. Morgan Healthcare Conference and RESI JPM 2025 in San Francisco, CA, from January 12-16, 2025! Join us to learn more about how Adovate is transforming innovation in adenosine-based therapeutics. Our CEO and Chairman, Bill Stilley, and CFO, Uday Gupta, are looking forward to connecting with industry leaders, investors, and innovators to share insights and explore potential collaborations. ?? Let's make meaningful connections! If you’ll be attending, don’t hesitate to reach out. Learn more about us at www.adovate.com. #JPM2025 #HealthcareInnovation #RESIConference #Biotech #Pharma #Collaboration #Adovate

Grateful for Acumen Pharmaceuticals, Inc. and Daniel O'Connell for their continued efforts in advancing human health and keeping Charlottesville on the map in this important fight!

I am about to wrap up my first attendance to the BioHealth Capital Region Forum and Investor Conference. Thank you to Richard Bendis, Andy Eckert, M.S., Brett Shealy, John Newby and others for putting on this incredible event to bring the #DMV #biotech community together. The team at Adovate is thrilled to be part of this rapidly growing ecosystem. The presence of Gov. Wes Moore and Gov Glenn Youngkin further highlights the ongoing investments being made to support this vital sector. Thank you to everyone who is supporting Adovate's mission to improve patient care worldwide. #vabio #biopharma #biotech

Meet us at #BIO2024! Exciting developments at Adovate! As a pioneering pharmaceutical company, we're dedicated to creating best-in-class, novel drug candidates. Our focus? Adenosine receptors—a key player in major diseases like #asthma, #cancer, and #diabetes. Using our advanced adenosine drug development platform, we are designing and producing groundbreaking compounds with superior characteristics.